- Home
- RNXT vs NXL Comparison
RNXT vs NXL Comparison
Compare RNXT & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- NXL
- Stock Information
- Founded
- RNXT 2012
- NXL 2010
- Country
- RNXT United States
- NXL United States
- Employees
- RNXT N/A
- NXL N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- NXL Medical Specialities
- Sector
- RNXT Health Care
- NXL Health Care
- Exchange
- RNXT Nasdaq
- NXL Nasdaq
- Market Cap
- RNXT 37.6M
- NXL 24.2M
- IPO Year
- RNXT 2021
- NXL 2022
- Fundamental
- Price
- RNXT $1.06
- NXL $1.25
- Analyst Decision
- RNXT Strong Buy
- NXL Strong Buy
- Analyst Count
- RNXT 2
- NXL 1
- Target Price
- RNXT $7.00
- NXL $5.00
- AVG Volume (30 Days)
- RNXT 117.4K
- NXL 134.5K
- Earning Date
- RNXT 05-15-2025
- NXL 05-20-2025
- Dividend Yield
- RNXT N/A
- NXL N/A
- EPS Growth
- RNXT N/A
- NXL N/A
- EPS
- RNXT N/A
- NXL N/A
- Revenue
- RNXT $43,000.00
- NXL $168,721.00
- Revenue This Year
- RNXT $4,755.81
- NXL $79.59
- Revenue Next Year
- RNXT $187.93
- NXL $334.65
- P/E Ratio
- RNXT N/A
- NXL N/A
- Revenue Growth
- RNXT N/A
- NXL 52.35
- 52 Week Low
- RNXT $0.75
- NXL $0.53
- 52 Week High
- RNXT $1.69
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- RNXT 60.35
- NXL 27.03
- Support Level
- RNXT $1.02
- NXL $1.15
- Resistance Level
- RNXT $1.09
- NXL $1.39
- Average True Range (ATR)
- RNXT 0.05
- NXL 0.14
- MACD
- RNXT 0.01
- NXL -0.04
- Stochastic Oscillator
- RNXT 80.00
- NXL 12.92
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.